Phase I study of DMT-210 in patients with moderate-to-severe acne rosacea.
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2016
At a glance
- Drugs DMT 200 (Primary)
- Indications Rosacea
- Focus Adverse reactions; First in man; Pharmacokinetics
- 28 Sep 2016 28-day top-line results published in Dermata Therapeutics media release.
- 30 May 2016 New trial record
- 16 May 2016 According to Dermata Therapeutics media release, the company plans to have top line results in the third quarter of this year (2016).